News | January 21, 2022
Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22
Biocon has reported consolidated financial results for the period ended December 31, 2021
Biocon has reported consolidated financial results for the period ended December 31, 2021
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
Ram’s appointment follows the launch of the CDI India division in October 2021.
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
He holds nine US patents and has published in multiple peer-reviewed journals and conferences
The tie-up combines Abbisko Therapeutics’ proprietary drug discovery platform with Lilly’s disease and discovery expertise
New capabilities on Philips Image Guided therapy mobile C-arm system – Zenition – and collaboration with Cydar offer the latest advances in endovascular treatment
_256_384.jpg)
Extending nonsurgical treatment options for Failing Pulmonic Valve in patients with congenital heart disease using Transcatheter Pulmonary Valve
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
Narayanan to lead SeQuent through next phase of consolidation and growth
Subscribe To Our Newsletter & Stay Updated
